Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Aeglea BioTherapeutics, Inc. | agle-ex322_7.htm |
| EX-32.1 - EX-32.1 - Aeglea BioTherapeutics, Inc. | agle-ex321_6.htm |
| EX-31.2 - EX-31.2 - Aeglea BioTherapeutics, Inc. | agle-ex312_8.htm |
| EX-31.1 - EX-31.1 - Aeglea BioTherapeutics, Inc. | agle-ex311_9.htm |
| EX-10.17 - EX-10.17 - Aeglea BioTherapeutics, Inc. | agle-ex1017_1102.htm |
| EX-10.12 - EX-10.12 - Aeglea BioTherapeutics, Inc. | agle-ex1012_1673.htm |
| 10-K - 10-K - Aeglea BioTherapeutics, Inc. | agle-10k_20171231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S‑3 (No. 333-217573) and Form S-8 (No. 333-216903 and No. 333-210633) of Aeglea BioTherapeutics, Inc. of our report dated March 13, 2018 relating to the financial statements, which appears in this Form 10‑K.
/s/ PricewaterhouseCoopers LLP
Austin, Texas
March 13, 2018